1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Hospital Infection Therapeutics Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020

Hospital Infection Therapeutics Industry: Forecasts to 2020

  • September 2014
  • 121 pages
  • ID: 3999616
In this report:
The hospital infection therapeutics market is also segmented on the basis of major hospital infection types, into six major categories, namely, hospital acquired pneumonia, urinary tract infections, gastrointestinal disorders, bloodstream infections, surgical site infections and other hospital infections.
This section of the report also deals with market attractiveness analysis, Porter’s five forces analysis and competitive analysis of the key players in 2013 in the global hospital infection therapeutics market.

Summary

Table of Contents

This market report on hospital infection therapeutics, studies the current as well as future prospects of the market globally. Hospital infections are also referred to as healthcare-associated infections, or nosocomial infections or hospital-acquired infection. HAIs can be defined as those infections that occur in patients when they are admitted to a hospital or any other health-care facility with which they were not suffering from at the time of their admission. A Hospital infection also comprises those infections that are acquired in the hospital but appear after the discharge of the patient, as well as the occupational infections among hospital staff. Different antimicrobial drugs have proven their effectiveness in treating a range of hospital infections that are globally recurrent at present. This business report comprises of a detailed executive summary, which comprises a market snapshot that offers global information of different segments and subsegments that are contained in the industry report. It also offers an global information and data analysis of the overall hospital infection therapeutics market with respect to market segments established on type of drugs used, main hospital infections and geographic regions.

The sector for hospital infection therapeutics is split into three main therapeutic drug types, that is, antibacterial, antiviral and antifungal drugs. The hospital infection therapeutics market is also divided based on main hospital infection types, into six main categories, that is, hospital acquired pneumonia, urinary tract infections, gastrointestinal disorders, bloodstream infections, surgical site infections and other hospital infections. The industry has been extensively analyzed based on the usefulness, effectiveness and sales revenue of main drug types as well as geographic prevalence of main types of hospital infections. The market size and forecast in terms of USD million for each drug as well as main infection types has been specified for the period 2012 to 2020, considering 2013 as the base year. The study also offers the compounded annual increase rate for each market segment for the forecast period 2014 to 2020.

Geographically, the hospital infection therapeutics market has been classified into four regions that is, North America continent, Europe (EU), Asia Pacific (APAC), and Rest of the globe. The market value and estimate for each of these regions has been specified for the period 2012 to 2020 along with the Compound annual growth rate for the forecast period 2014 to 2020. The study also includes a section on pipeline analysis for this sector that contains sales forecast for several drugs currently under phase III clinical trials and anticipated to be launched during the outlook period. Main pipeline drugs that have been included in the market research are Amikacin Inhale, CAZ AVI, Ceftolozane/Tazobactam, Dalvance, Delafloxacin, Eravacycline, MK-3415A, Oritavancin, Plazomicin, Surotomycin and Tedizolid. The business research study also incorporates the challenging scenario in these areas. A in-depth qualitative analysis of the factors responsible for driving and restraining the growth of this market and future opportunities has been specified in the market survey part. This section of the report also deals with Analysis of market appeal, Porter's five forces analysis and ambitious analysis of the main players in 2013 in the overall hospital infection therapeutics market.

A list of recommendations has been specified for additional entrants as well as existing market players to help them establish a strong presence in the sector and increase their share. The report also profiles main players of the hospital infection therapeutics market based on different attributes including company overview, financial review, strategic management, product portfolio and recent evolutions. Some of the Main actors described in this study include Actavis plc, AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Cubist Pharmaceuticals, Incorporated, GlaxoSmithKline plc, Johnson & Johnson Services, Incorporated, Merck & Co., Incorporated, Pfizer, Incorporated, and Sanofi.

The overall hospital infection therapeutics segment is split as follows:

Hospital Infection Therapeutics Market, by Drug Type

Hospital Infection Therapeutics Market, by Geography

North America (NA)

Europe (EU)

Asia-Pac

Rest of the globe

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Veronica helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Peanut Allergy: Opportunity Analysis and Forecasts to 2027

Peanut Allergy: Opportunity Analysis and Forecasts to 2027

  • $ 10995
  • Industry report
  • June 2018
  • by GlobalData

Peanut Allergy: Opportunity Analysis and Forecasts to 2027SummaryGlobal Peanut Allergy marketplace (8 major pharmaceutical markets - US, France, Germany, Italy, Spain, UK, Canada, and Australia) is to ...

Ulcerative Colitis: Global Drug Forecast and Market Analysis to 2026

Ulcerative Colitis: Global Drug Forecast and Market Analysis to 2026

  • $ 10995
  • Industry report
  • June 2018
  • by GlobalData

Ulcerative Colitis: Global Drug Forecast and Market Analysis to 2026SummaryThe current Ulcerative Colitis (UC) market is overcrowded with cheap generic drugs for mild to moderate disease, as well as expensive ...

Market Access, Pricing and Reimbursement of Oncology Medicines in the 5EU

Market Access, Pricing and Reimbursement of Oncology Medicines in the 5EU

  • $ 7995
  • Industry report
  • September 2018
  • by GlobalData

Market Access, Pricing and Reimbursement of Oncology Medicines in the 5EUSummaryMarket access of oncology medicines is increasingly challenging due to the rising cost of new and innovative medicines, more ...

Biosimilars in Oncology $ 7995 August 2018


ref:plp2014

Reportlinker.com © Copyright 2018. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on